VitaPCR™Sample Collection Buffer Shows the Capability of Inactivating the SARS-CoV-2 Virus, Influenza A Virus, Influenza B Virus, and Respiratory Syncytial Virus (RSV)
Taiwan, January 14, 2022–SARS-CoV-2, Influenza vi […]
Taiwan, January 14, 2022–SARS-CoV-2, Influenza vi […]
Focusing on research and development of revolutionary diagnostic technologies since 2011, Credo Diagnostics develops, manufactures, and commercializes accurate, rapid, and affordable molecular diagnostic solutions at the Point-Of-Care testing.
© 2023 | Credo Diagnostics Biomedical Pte. Ltd.
